Position in ADCT
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$270,303
-$1,792 QoQ
Shares Held
72,081
-6.5% QoQ
Ownership
0.057%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ADCT Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026DAFNA Capital Management LLC holds $21,126,826 across 6 Drug Manufacturers - Specialty & Generic names. ADCT ranks #6 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
70,615 | $9,302,820 | |
| 2 | ALKS |
Alkermes plc.
|
139,482 | $4,932,083 | |
| 3 | BCRX |
Biocryst Pharmaceuticals Inc
|
430,248 | $4,095,960 | |
| 4 | AQST |
Aquestive Therapeutics, Inc.
|
368,415 | $1,528,922 | |
| 5 | SCYX |
Scynexis Inc
|
1,086,956 | $996,738 | |
| 6 | ADCT |
ADC Therapeutics SA
This page
|
72,081 | $270,303 |
All Filings in ADCT
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $270,303 | 72,081 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $272,095 | 77,081 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $488,324 | 122,081 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $327,177 | 122,081 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $315,954 | 224,081 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $445,921 | 224,081 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $642,855 | 204,081 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $644,895 | 204,081 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||